GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ginwa Enterprise Group Inc (SHSE:600080) » Definitions » Net Change in Cash

Ginwa Enterprise Group (SHSE:600080) Net Change in Cash : ¥-244.5 Mil (TTM As of Mar. 2025)


View and export this data going back to 1997. Start your Free Trial

What is Ginwa Enterprise Group Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Ginwa Enterprise Group's Net Change in Cash for the three months ended in Mar. 2025 was ¥-219.5 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 was ¥-244.5 Mil.

Ginwa Enterprise Group Net Change in Cash Historical Data

The historical data trend for Ginwa Enterprise Group's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ginwa Enterprise Group Net Change in Cash Chart

Ginwa Enterprise Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.08 -209.15 274.37 187.09 -281.81

Ginwa Enterprise Group Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -256.74 -60.43 -45.95 81.30 -219.47

Ginwa Enterprise Group Net Change in Cash Calculation

Ginwa Enterprise Group's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=10.859+-192.304+-100.367+0
=-281.8

Ginwa Enterprise Group's Net Change in Cash for the quarter that ended in Mar. 2025

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-121.369+-132.575+34.473+0
=-219.5

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-244.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ginwa Enterprise Group Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Ginwa Enterprise Group's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Ginwa Enterprise Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ginwa Enterprise Group Inc (SHSE:600080) » Definitions » Net Change in Cash
Comparable Companies
SZSE:301331 SZSE:000153 SHSE:600594 SZSE:002940 SHSE:603079 SHSE:600568 SZSE:002107 SHSE:600513 SZSE:300534 SZSE:300452 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
N/A
Address
Gaoxin 3rd Road, 40th Floor, South Tower, Phase III, Fortune Center, Gaoxin District, Xi'an, CHN, 710075
Website
http://www.ginwa.com
Ginwa Enterprise Group Inc operates in the pharmaceutical industry. The main business is the research and development, production, and sales of drugs, and the product line covers chemical drugs, Chinese patent medicines, raw materials, and health products. The dosage forms include tablets, capsules, granules, powders, mixtures, oral solutions, syrups, external solutions, and more than 100 varieties and specifications.
Executives
Zhang Chao Yang Director
Zhang Mei Director
Tao Yu senior management
Qin Chuan Director
Hou Yi Wen senior management
Ge Xiu Li Supervisors

Ginwa Enterprise Group Headlines

No Headlines